Aprotinin, Blood Loss, and Renal Dysfunction in Deep Hypothermic Circulatory Arrest
Authors: Mora Mangano Christina T. , Neville Michael J. , Hsu Ping H. , Mignea Iulia , King Jennifer , Miller D.Craig 
Published: July 2021

Background

The technique of deep hypothermic circulatory arrest (DHCA) for cardiothoracic surgery is associated with increased risk for perioperative blood loss and renal dysfunction. Although aprotinin, a serine protease inhibitor, reduces blood loss in patients undergoing cardiopulmonary bypass, its use has been limited in the setting of DHCA because of concerns regarding aprotinin-induced renal dysfunction. Therefore, we assessed the affect of aprotinin on both blood transfusion requirements and renal function in patients undergoing cardiovascular surgery and DHCA.

Methods and Results

We reviewed the records of 853 patients who underwent aortic or thoracoabdominal surgery at Stanford University Medical Center between January 1992 and March 2000. Two hundred three of these patients were treated with DHCA, and 90% (183) survived for more than 24 hours. Preoperative patient characteristics and intraoperative and postoperative clinical and surgical variables were recorded, and creatinine clearance (CRCl) was calculated for the preoperative and postoperative periods; renal dysfunction was prospectively defined as a 25% reduction in CRCl. The association between perioperative variables, including aprotinin use, and renal dysfunction was assessed by ANOVA techniques. Total urine output was 1294±1024 mL and 3492±1613 mL during and after surgery, respectively. CRCl decreased significantly after DHCA from 86±8 mL/min (before surgery) to 67±4 mL/min (in the intensive care unit) (
P
<0.01). Thirty-eight percent of patients (70 of 183) had postoperative renal dysfunction. Multivariate regression analyses identified 5 factors independently associated with a >25% reduction in CRCl: requirement for ≥5 U of packed red blood cells(
P
=0.0002; OR=2.1), ≤800 mL of urine collected in the operating room (
P
=0.0011; OR=1.9), nonuse of dopamine (
P
=0.0430; OR=1.6), hematocrit ≤21 mg% (
P
=0.0343; OR=1.5), and ≤2100 mL of urine during the first 24 hours in the intensive care unit (
P
=0.0039; OR=2.0). Aprotinin did not increase the likelihood of postoperative renal dysfunction (
P
=0.951), nor did it significantly reduce packed red blood cell transfusion requirements in either primary (n=107) (
P
=0.456) or reoperative cardiovascular (n=76) (
P
=0.176) procedures. During the operative period, the aprotinin group received a greater number of units of platelets (10.0 versus 6.6 U,
P
<0.012), fresh frozen plasma (4.8 versus 3.1 U,
P
<0.03), and cryoprecipitate (9.9 versus 5.4 U,
P
<0.002) than patients not prescribed aprotinin. Similarly, patients given aprotinin received more cryoprecipitate in the intensive care unit (7.3 versus 3.0 U,
P
<0.024).

Conclusions

These data suggest that the administration of aprotinin to patients treated with DHCA does not increase the risk of renal dysfunction. However, aprotinin may not ameliorate the problem of perioperative blood loss in DHCA. Patients with greater requirements for packed red blood cell transfusions or reduced urine production are more likely to have postoperative renal dysfunction. Dopamine may provide renal protection in the setting of DHCA.